vs
Immunovant, Inc.（IMVT）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
Immunovant, Inc.的季度营收约是Lakeside Holding Ltd的1.2倍（$8.4M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -899.0%，领先876.4%），Immunovant, Inc.同比增速更快（140.7% vs 95.0%）
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
IMVT vs LSH — 直观对比
营收规模更大
IMVT
是对方的1.2倍
$7.0M
营收增速更快
IMVT
高出45.7%
95.0%
净利率更高
LSH
高出876.4%
-899.0%
损益表 — Q4 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $7.0M |
| 净利润 | $-75.3M | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | -896.2% | -21.3% |
| 净利率 | -899.0% | -22.6% |
| 营收同比 | 140.7% | 95.0% |
| 净利润同比 | -26.7% | 18.7% |
| 每股收益（稀释后） | $-0.50 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMVTLSH
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | — | $6.3M | ||
| Q1 25 | — | $3.8M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.1M | ||
| Q1 24 | $8.4M | — | ||
| Q4 23 | $8.9M | — |
净利润IMVTLSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-893.1K | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | $-1.3M | ||
| Q1 24 | $-75.3M | — | ||
| Q4 23 | $-51.4M | — |
毛利率IMVTLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
营业利润率IMVTLSH
| Q4 25 | — | -21.3% | ||
| Q3 25 | — | -20.8% | ||
| Q2 25 | — | -8.9% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | — | -32.5% | ||
| Q1 24 | -896.2% | — | ||
| Q4 23 | -576.8% | — |
净利率IMVTLSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | — | -22.2% | ||
| Q2 25 | — | -14.2% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | — | -32.7% | ||
| Q1 24 | -899.0% | — | ||
| Q4 23 | -575.6% | — |
每股收益（稀释后）IMVTLSH
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $-0.18 | ||
| Q1 24 | $-0.50 | — | ||
| Q4 23 | $-0.36 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.4M | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $617.8M | $12.2M |
| 总资产 | $666.4M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资IMVTLSH
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $2.7M | ||
| Q1 24 | $635.4M | — | ||
| Q4 23 | $690.9M | — |
总债务IMVTLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
股东权益IMVTLSH
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $2.8M | ||
| Q1 25 | — | $749.8K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $3.6M | ||
| Q1 24 | $617.8M | — | ||
| Q4 23 | $679.3M | — |
总资产IMVTLSH
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $18.6M | ||
| Q2 25 | — | $14.4M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $10.8M | ||
| Q1 24 | $666.4M | — | ||
| Q4 23 | $711.4M | — |
负债/权益比IMVTLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.7M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | — |
| 自由现金流率自由现金流/营收 | -714.4% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-214.6M | — |
8季度趋势，按日历期对齐
经营现金流IMVTLSH
| Q4 25 | — | $-453.5K | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $-483.7K | ||
| Q1 25 | — | $-238.3K | ||
| Q4 24 | — | $-530.2K | ||
| Q3 24 | — | $-1.4M | ||
| Q1 24 | $-59.7M | — | ||
| Q4 23 | $-47.1M | — |
自由现金流IMVTLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M | ||
| Q1 24 | $-59.8M | — | ||
| Q4 23 | $-47.2M | — |
自由现金流率IMVTLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% | ||
| Q1 24 | -714.4% | — | ||
| Q4 23 | -528.7% | — |
资本支出强度IMVTLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% | ||
| Q1 24 | 1.8% | — | ||
| Q4 23 | 1.5% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMVT
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
